Amgen, a biotechnology company that has carved out a significant place in the pharmaceutical landscape, is now attempting to challenge industry giants Eli Lilly and Novo Nordisk in the GLP-1 space. With a new experimental obesity drug in the works, Amgen aims to provide an alternative for millions of patients seeking effective weight loss solutions.…